SLG
RNAC icon

Stanley-Laman Group’s Cartesian Therapeutics RNAC Stock Holding History

Stanley-Laman Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,365
Closed -$402K – 275
2017
Q4 		$402K Buy
+1,365
New +$596K 0.09% 237

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stanley-Laman Group's RNAC Position: Q1 2018 in Review

Stanley-Laman Group sold out of Cartesian Therapeutics (RNAC) in Q1 2018, closing a stake of 1,365 shares — an estimated $402K sold.

Stanley-Laman Group first reported a position in RNAC in Q4 2017 and held it in 1 quarter. The position peaked at $402K in Q4 2017. 59 funds tracked by Wall St. Rank hold RNAC as of Q1 2018.

  • Stanley-Laman Group reported no remaining Cartesian Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 1,365 Cartesian Therapeutics shares in Q1 2018, an estimated $402K.
  • Stanley-Laman Group first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 1 quarter.
  • Stanley-Laman Group's Cartesian Therapeutics position peaked at $402K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2018.

Based on Stanley-Laman Group's 13F filing for Q1 2018, filed 1 May 2018.